Progress in Clinical Development for Alzheimer´s and Other Indications: Galimedix Therapeutics Successfully Completes Phase 1 Study With Oral Small Molecule, GAL-101, an Amyloid Beta Aggregation Modulator
You are currently viewing a placeholder content from Elfsight. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
